消除对BRAF靶向治疗的一丝疑虑。
Removing a hair of doubt about BRAF targeting.
作者信息
Kreitman Robert J
机构信息
NATIONAL INSTITUTES OF HEALTH.
出版信息
Blood. 2015 Feb 19;125(8):1199-200. doi: 10.1182/blood-2014-12-616318.
Abstract
In this issue of Blood, Pettirossi et al, including Drs Tiacci and Falini, who led the effort in 2011 defining the BRAF-V600E driving mutation in hairy cell leukemia (HCL),provide extensive laboratory studies showing that inhibitors of BRAF-V600E and/or mitogen-activated protein kinase kinase (MEK) reach their targets and cause HCL cell death
摘要
在本期《血液》杂志中，佩蒂罗西等人，包括2011年率先确定毛细胞白血病（HCL）中BRAF-V600E驱动突变的蒂亚奇博士和法利尼博士，提供了大量实验室研究，表明BRAF-V600E和/或丝裂原活化蛋白激酶激酶（MEK）抑制剂能够作用于其靶点并导致HCL细胞死亡。
相似文献
1
Removing a hair of doubt about BRAF targeting.消除对BRAF靶向治疗的一丝疑虑。
Blood. 2015 Feb 19;125(8):1199-200. doi: 10.1182/blood-2014-12-616318.
2
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.BRAF抑制剂可逆转毛细胞白血病独特的分子特征和表型，并发挥强大的抗白血病活性。
Blood. 2015 Feb 19;125(8):1207-16. doi: 10.1182/blood-2014-10-603100. Epub 2014 Dec 5.
3
BRAF inhibitor therapy in HCL.毛细胞白血病中的BRAF抑制剂疗法。
Best Pract Res Clin Haematol. 2015 Dec;28(4):246-52. doi: 10.1016/j.beha.2015.10.001. Epub 2015 Oct 20.
4
Hairy cell leukemia: update and current therapeutic approach.毛细胞白血病：最新进展与当前治疗方法
Curr Opin Hematol. 2015 Jul;22(4):355-61. doi: 10.1097/MOH.0000000000000154.
5
BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.维莫非尼低剂量治疗毛细胞白血病的 BRAF 抑制作用。
Blood. 2016 Jun 9;127(23):2847-55. doi: 10.1182/blood-2015-11-680074. Epub 2016 Mar 3.
6
Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.低剂量维莫非尼使一例伴有V600E突变的毛细胞白血病患者实现完全缓解。
Haematologica. 2013 Feb;98(2):e20-2. doi: 10.3324/haematol.2012.082404. Epub 2013 Jan 8.
7
Improved overall survival in melanoma with combined dabrafenib and trametinib.达拉非尼和曲美替尼联合治疗可改善黑色素瘤患者的总生存期。
N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.
8
Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.通过使用ganetespib靶向抑制Hsp90克服黑色素瘤中获得性BRAF抑制剂耐药性。
Mol Cancer Ther. 2014 Feb;13(2):353-63. doi: 10.1158/1535-7163.MCT-13-0481. Epub 2014 Jan 7.
9
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.转移性黑色素瘤患者中使用靶向MAPK通路药物治疗相关不良事件的管理
Oncologist. 2017 Jul;22(7):823-833. doi: 10.1634/theoncologist.2016-0456. Epub 2017 May 18.
10
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.达拉非尼联合曲美替尼与维莫非尼单药治疗不可切除或转移性皮肤 BRAF Val600 突变阳性黑色素瘤患者的健康相关生活质量比较（COMBI-v）：一项开放标签、随机、3 期临床试验结果。
Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X.
本文引用的文献
1
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.BRAF抑制剂可逆转毛细胞白血病独特的分子特征和表型，并发挥强大的抗白血病活性。
Blood. 2015 Feb 19;125(8):1207-16. doi: 10.1182/blood-2014-10-603100. Epub 2014 Dec 5.
2
Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?复发难治性BRAF阴性、IGHV4-34阳性毛细胞白血病变体：一种独特的实体？
J Clin Oncol. 2016 Mar 1;34(7):e57-60. doi: 10.1200/JCO.2013.50.9661. Epub 2014 Jun 30.
3
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.毛细胞白血病中 BRAFV600E 突变的造血干细胞起源。
Sci Transl Med. 2014 May 28;6(238):238ra71. doi: 10.1126/scitranslmed.3008004.
4
High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.高表达 MAP2K1 突变的变异型和 IGHV4-34 表达的毛细胞白血病。
Nat Genet. 2014 Jan;46(1):8-10. doi: 10.1038/ng.2828. Epub 2013 Nov 17.
5
Hairy cell leukemia-new genes, new targets.毛细胞白血病——新基因，新靶点。
Curr Hematol Malig Rep. 2013 Sep;8(3):184-95. doi: 10.1007/s11899-013-0167-0.
6
Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib.双等位基因BRAF V600E突变的毛细胞白血病对低剂量维莫非尼的快速反应
Br J Haematol. 2013 Apr;161(1):150-3. doi: 10.1111/bjh.12201. Epub 2012 Dec 29.
7
BRAF inhibition in refractory hairy-cell leukemia.BRAF抑制在难治性毛细胞白血病中的应用
N Engl J Med. 2012 May 24;366(21):2038-40. doi: 10.1056/NEJMc1202124.
8
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.两种变体和表达IGHV4-34 的毛细胞白血病均缺乏 BRAF V600E 突变。
Blood. 2012 Apr 5;119(14):3330-2. doi: 10.1182/blood-2011-09-379339. Epub 2011 Dec 30.
9
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.克拉屈滨序贯利妥昔单抗治疗慢性淋巴细胞白血病的Ⅱ期临床研究
Blood. 2011 Oct 6;118(14):3818-23. doi: 10.1182/blood-2011-04-351502. Epub 2011 Aug 5.
10
BRAF mutations in hairy-cell leukemia.弥漫性大 B 细胞淋巴瘤中 BRAF 基因突变。
N Engl J Med. 2011 Jun 16;364(24):2305-15. doi: 10.1056/NEJMoa1014209. Epub 2011 Jun 11.
Zotero 插件